1. Generics Bulletin
  2. >>Legal & IP

Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe

 
• By Brenda Sandburg

Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.

Washington DC - Department of Justice Building
US Department of Justice, Washington DC

Heritage Pharmaceuticals Inc. is paying a relatively small sum to be free of the US Department of Justice's industry wide probe of generic price fixing. It remains to be seen if other generic manufacturers will enter similar settlements and how great their liability might be.

Heritage agreed to pay $7.1m to resolve allegations under the False Claims Act that it engaged in a price-fixing conspiracy....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

UPC Imposes Wide Cross-Border Injunction On Zentiva In Ofev Patent Clash

 
• By Dean Rudge

The UPC Court of Appeal has signaled that in pharma disputes, being ready to launch can be as risky as actually launching. In a major setback for Zentiva, the court ruled that completing certain steps well before patent expiry amounted to “setting the stage” for infringement.

UK Decision Opens Up Competition On Forxiga

 
• By Dave Wallace

Generic dapagliflozin rivals to AstraZeneca’s Forxiga are now free to hit the UK market after the country’s Supreme Court lifted the final barrier preventing launch, allowing off-patent firms access to a market worth hundreds of millions of pounds annually.

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

 
• By Dean Rudge

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

More from Generics Bulletin

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By Dean Rudge

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Fresenius Kabi Pharma Bounces Back In Q2 With Strong US and Europe Volumes

 
• By Dean Rudge

Fresenius Kabi’s IV drugs and fluids Pharma division rebounded in Q2, led by strong US and European volumes, especially in infusion therapies. Biopharma revenue rose by 26% to €190m, up one-third in constant currencies, driven by tocilizumab biosimilar ramp-up in Europe and the US.

UPC Imposes Wide Cross-Border Injunction On Zentiva In Ofev Patent Clash

 
• By Dean Rudge

The UPC Court of Appeal has signaled that in pharma disputes, being ready to launch can be as risky as actually launching. In a major setback for Zentiva, the court ruled that completing certain steps well before patent expiry amounted to “setting the stage” for infringement.